

## Special Issue

# Genome Instability and Human Cancer

### Message from the Guest Editor

Genomic instability is not only a hallmark of cancer but also an enabling characteristic that fuels cancer progression. Genomic instability in cancer cells also contributes to the evolving intra-tumor heterogeneity and the rise of drug-resistant cancer cells after chemotherapy or targeted therapy. However, cancer cells still need to maintain their genomes in a delicate stability to avoid the cellular catastrophe, which could be triggered by excessive instability in the genome. Cancer cells depend on various mechanisms to suppress their genomic instability from reaching a catastrophic point, which constitutes a vulnerability that can be exploited for therapeutic interventions. Targeting cancer-cell-specific dependency on mechanisms that suppress the genomic instability may create a synthetic lethality scenario that could kill cancer cells specifically or boost tumor-targeted immunity by activating an innate immune response, enhancing the intrinsic immunogenicity of cancer cells, or modulating the tumor microenvironment.

### Guest Editor

Dr. Jian Ouyang

Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA

### Deadline for manuscript submissions

15 December 2025



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/190917](https://mdpi.com/si/190917)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)